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Testotoxicosis: gonadotrophin - independent male sexual
precocity
ArifAbdul Aziz, S.M.W. Jafri and Naeem Ul Haque
Department ofMedicine, The Aga Khan University Hospital, Stadium Road, PO Box 3500, Karachi 74800,
Pakistan
Summary: In this era of rapidly developing investigational tools and pharmacology, the patho-
physiology of precocious puberty is becoming well defined. What was previously thought to be a form of
gonadotrophin releasing hormone (GNRH)-dependent central precocious puberty is now classified as
GNRH-independent familial testotoxicosis. We present two such cases and review the clinical features,
pathophysiology and treatment of testotoxicosis.
Introduction
Sexual precocity is defined as the appearance of
physical signs of puberty before 8 years of age in
females or 9 years of age in males. The clinical
disorders that induce sexual precocity can be
classified as gonadotrophin releasing hormone
(GNRH) dependent or GNRH independent.'
Male sexual precocity first described as a form of
central precocious puberty has recently been char-
acterized as a familial intratesticular disorder.2'3
Sexual development, symmetrical testicular enlarge-
ment and accelerated rate of growth are noted by
3 -4 years ofage."3 The pulsatile pattern ofluteiniz-
ing hormone (LH) secretion and the immuno-
reactive and bioactive LH responses to GNRH are
similar to these seen in prepubertal children despite
markedly elevated concentrations of serum testos-
terone. We describe two sporadic cases and will
review clinical features, diagnosis and treatment of
testotoxicosis.
Case report
Case I
The first patient, born in December 1986, the
product of normal pregnancy delivered by Caesa-
rean section due to transverse lie, weighed
approximately 6 lb at birth. The mother took no
medications during pregnancy. He was noted to
have a rather large penis at 6 weeks of age when he
was circumcised. At the age of 6-9 months pubic
hairs were noted. At age 2 years his height was
99.7 cm and weight was approximately 15 kg both
being above 97th percentile. He had a bone age of
6.4 years. He had stage IV genital development,
Stage IV pubic hair and testicular volume of 8 ml
(Figures 1 and 2). His voice was husky and he was
extremely hirsute. There was no family history of
precocious puberty. Reports of hormonal assays
are shown in Table I. An overnight gonadotrophin
profile showed low level pulsatility of LH but no
measurable follicle stimulating hormone (FSH).
Testicular biopsy showed Leydig cell hyperplasia.
An injection of Lupron (LHRH agonist) increased
serum testosterone to 1064.8 ng/dl. Computed
tomographic (CT) scan of the brain and adrenal
was normal as was ultrasound of the testes and
adrenals.
Case 2
This patient presented to us at 8 years of age. He
was born full term and there was no history of any
drug intake except diazepam by his mother. At 3
years of age he was found to have enlargement of
the penis and appearance of pubic hair. At presen-
tation his height was 135 cm and weight was 32 kg.
There were downy facial hairs. Axillary hairs were
present. The penis was 7-8 cm in length and pubic
hair was Tanner Stage IV. The right testis was
10 ml in volume and the left was 12 ml. Investiga-
tions revealed a bone age of 14 years. X-ray skull
and CT scan of brain were normal. Hormonal
assay results are shown in Table I.
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Figure 2 Case 2. The patient aged 2 years.
Table I Endocrine screening
Case Case Normal
Hormone 1 2 range
Serum testosterone (ng/dl) 598.0 631.0 4.1-9.1
Dehydroepiandrostenedione 21.4 310.5 60-254
(tg/dl)
Serum follicle stimulating < 1.5 < 1.7 1-16
hormone (mIU/ml)
Serum luteinizing hormone < 2.8 < 1.0 1.8-6.0
(mIU/ml)
Figure 1 Case 1. The patient aged 2 years.
Discussion
Testotoxicosis or familial male precocious puberty
is a form of isosexual precocious puberty, that is
independent of gonadotrophin releasing hormone.
The pattern of inheritance is autosomal dominant,
although sporadic cases can occur.4 Transmission
is through affected males or carrier females to their
sons.
Clinical features are characterized by sexual
development, symmetrical testicular enlargement
and acclerated rate of growth seen by 3-4 years of
age. Enlargement of external genitalia may be
noted as early as birth.5 The testes may be appropri-
ate in size or slightly small in relation to the stage of
sexual maturation. Rapid virilization and prema-
ture epiphyseal fusion results in short adult sta-
6,7ture.7
The hypothalamic-pituitary gonadotrophin unit
operates at a prepubertal level in these patients.8
The characteristic findings are low basal gonado-
trophin levels, absence of sleep-associated LH
pulses and lack of a pubertal-type rise in LH
concentration after luteinizing hormone releasing
factor (LHRF). However, affected adults show a
mature LH response to LHRF, whereas FSH is
elevated in adults with seminiferous tubule
damage, provding evidence that central regulatory
pathways are intact. There is lack of excessive
testosterone response to administration of human
chorionic gonadotrophin (HCG) in boys and
absence of testosterone increase after LHRF in
adults, despite substantial rises in plasma LH
levels. All the above findings are consistent with a
primary testicular defect.' Testicular histology
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shows hyperplasia ofLeydig cells.9 In some affected
adults, germ cell degeneration, progressive dys-
function of spermatogenesis and elevated levels of
FSH have been observed.9 '0
The pathophysiology of premature Leydig cell
activation has still not been clearly elucidated.
Salient features of various hypotheses are as fol-
lows. Negative LH-HCG activity by bioassay
argues against the presence of a circulating
gonadotrophin-like factor.3'5 In addition, indirect
immunofluorescence studies have been unable to
identify a serum immunoglobulin in these patients,
comparable to thyroid stimulating hormone
immunoglobulin in thyrotoxic patients. Derange-
ment of an intratesticular regulatory mechanism
that inhibits Leydig cell function leading to unre-
strained activity of these cells has also been pro-
posed.3"''3 Premature Leydig cell activation may
also result from local production of a stimulatory
factor not detectable in the circulation that stimu-
lates CAMP-dependent kinase to induce testoster-
one secretion. For example, immunoreactive
HCG-like material has been identified in extracts of
human testes and other tissues,3'14 and human fetal
testes appear able to synthesize HCG.3"5
Various treatment options have been proposed
for testotoxicosis. Initial reports showed that
medroxyprogesterone acetate and anti-androgen
cypropterone acetate may have some therapeutic
benefit.5"0 The mode of action of ketoconazole is
inhibition of synthesis ofboth adrenal and gonadal
steroids.'01"67 The disadvantages of ketoconazole
are its potential hepatotoxicity and the fact that its
use is limited to those patients whose bone age has
reached pubertal age.'0 Another approach is block-
ade of androgen action with spironolactone.4"82'
The commonest problem with spironolactone is
development of gynaecomastia. Evidence that oes-
trogens may have an important role in the male
pubertal growth spurt22-24 has led to the use of
testolactone, a competitive inhibitor of the enzyme
aromatase, which converts androgens to oestro-
gens.25127 There is recent evidence that combination
of spironolactone and testolactone may be more
beneficial than either alone.4
In conclusion familial testotoxicosis is a disorder
of male isosexual precocity that is inherited as
an autosomal dominant condition (although spor-
adic cases can occur) characterized by gonado-
trophin-independent testicular hypersecretion.
This condition should be differentiated from gona-
dotrophin-dependent true precocious puberty as
treatment with LHRH analogues may aggravate
testotoxicosis. Treatment has not yet been well
defined and should be individualized for each case.
We believe our two cases either represent sporadic
cases or may be a new gene mutation in these two
families; long-term follow-up may answer the issue.
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